Search research articles
Contact Us
Filters
Showing results (181-190 of 247) with videos related to
Page
of 25
Sort By:
Neurology
|
December 6, 2013
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS
Giovanni Ristori, Silvia Romano, Stefania Cannoni, et al.
JAMA Network Open
|
September 28, 2022
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial
Patrick Vermersch, Matthew Scaramozza, Seth Levin, et al.
Scientific Reports
|
September 14, 2022
Cerebrovascular reactivity in multiple sclerosis is restored with reduced inflammation during immunomodulation
Antonio Maria Chiarelli, Alessandro Villani, Daniele Mascali, et al.
Therapeutic Advances in Neurological Disorders
|
September 25, 2023
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
Alasdair J Coles, Anat Achiron, Anthony Traboulsee, et al.
Journal of Neurology
|
January 26, 2021
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
Matteo Lucchini, Luca Prosperini, Maria Chiara Buscarinu, et al.
Neurology
|
September 14, 2014
Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up
Maria P Amato, Benedetta Goretti, Angelo Ghezzi, et al.
JAMA Neurology
|
March 29, 2021
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
Ludwig Kappos, Robert J Fox, Michel Burcklen, et al.
Neurology
|
April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
Scott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Therapeutic Advances in Neurological Disorders
|
September 14, 2018
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
Emanuele D'Amico, Aurora Zanghì, Graziella Callari, et al.
Neurology
|
July 2, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
Scott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Page
of 25
Search research articles
Search
Showing results (181-190 of 247) with videos related to
Sort By:
Page
of 25
Neurology
|
December 6, 2013
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS
Giovanni Ristori, Silvia Romano, Stefania Cannoni, et al.
JAMA Network Open
|
September 28, 2022
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial
Patrick Vermersch, Matthew Scaramozza, Seth Levin, et al.
Scientific Reports
|
September 14, 2022
Cerebrovascular reactivity in multiple sclerosis is restored with reduced inflammation during immunomodulation
Antonio Maria Chiarelli, Alessandro Villani, Daniele Mascali, et al.
Therapeutic Advances in Neurological Disorders
|
September 25, 2023
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
Alasdair J Coles, Anat Achiron, Anthony Traboulsee, et al.
Journal of Neurology
|
January 26, 2021
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
Matteo Lucchini, Luca Prosperini, Maria Chiara Buscarinu, et al.
Neurology
|
September 14, 2014
Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up
Maria P Amato, Benedetta Goretti, Angelo Ghezzi, et al.
JAMA Neurology
|
March 29, 2021
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
Ludwig Kappos, Robert J Fox, Michel Burcklen, et al.
Neurology
|
April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
Scott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Therapeutic Advances in Neurological Disorders
|
September 14, 2018
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
Emanuele D'Amico, Aurora Zanghì, Graziella Callari, et al.
Neurology
|
July 2, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
Scott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Page
of 25